Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
01
Overview
Terran Biosciences develops transformative therapeutics and technologies targeting neurological and psychiatric diseases. Its portfolio includes late-stage drug candidates for schizophrenia and Alzheimer’s disease, selective serotonin antagonists, a proprietary drug design engine enabling first-in-class psychedelic therapies, and an FDA-cleared AI-enabled neuromelanin MRI analysis platform. Lead programs have demonstrated significant efficacy in Phase II studies as adjunctive therapy in schizophrenia.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small moleculeProdrugSoftware as a medical deviceExtended-release formulation
- Industry
- Biotech
02
Partnerships
Pierre Fabre (“Idazoxan XR”—global development/commercialization rights licensed from Pierre Fabre)
Beyond the preview
Go deeper on Terean.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Terean.